Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 236

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Circulating microRNA-92a and microRNA-21 as novel minimally invasive biomarkers for primary breast cancer

Open access
Si, Haiyan, Sun, Xiaoming, Chen, Yingjian, Cao, Yuan, Chen, Shimin, Wang, Huanchun, Hu, Chengjin·2013·Journal of Cancer Research and Clinical Oncology

Abstract

PURPOSE: MicroRNAs (miRNAs) play an essential role in breast malignant tumor development and progression. The development of clinically validated biomarkers for primary breast cancer (BC) has remained an insurmountable task despite other advances in the field of cancer molecular biology. The objective of this study is to investigate the differential expression of miRNAs and the potential of circulating microRNAs as novel primary breast cancer biomarkers. METHODS: Our analyses were performed on 48 tissue and 100 serum samples of patients with primary BC and a set of 20 control samples of healthy women, respectively. The relative expression of ten candidate miRNAs (miR-106b, miR-125b, miR-17, miR-185, miR-21, miR-558, miR-625, miR-665, miR-92a, and miR-93) from the results of four bioinformatics approaches and literature curation was measured by real-time quantitative reverse transcription PCR (qRT-PCR). RESULTS: The level of miR-92a was significantly lower, while miR-21 was higher, as previous reports, in tissue and serum samples of BC than that of healthy controls (p < 0.001). Logistic regression and receiver operating characteristic curve analyses revealed the significant and independent value (p < 0.001) of the miR-92a and miR-21 expression quantification in serums. Moreover, the comparison with the clinicopathologic data of the BC patients showed that decreased levels of miR-92a and increased levels of miR-21 were associated with tumor size and a positive lymph node status (p < 0.001). CONCLUSIONS: These findings suggest that many miRNAs expressions are altered in BC, whose expression profiling may provide a useful clue for the pathophysiological research. Circulating miR-92a has potential use as novel breast cancer biomarker, which is comparable to miR-21.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00432-012-1315-y

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 236

Metadata

Authors
Si, H., Sun, X., Chen, Y., Cao, Y., Chen, S., Wang, H., & Hu, C.
Venue
Journal of Cancer Research and Clinical Oncology
Published
2012-09-30
Volume
139
Issue
2
Pages
223-229
ISSN
  • 0084-5353 (ISSN-L)
  • 0171-5216
  • 1432-1335
OpenAlex
W1981170620
Cited by
236
References
3
FWCI
7.26
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Circulating microRNA-92a and microRNA-21 as novel minimally invasive biomarkers for primary breast cancer. https://app.cochat.ai/papers/10.1007/s00432-012-1315-y
The paper
Si, H., Sun, X., Chen, Y., Cao, Y., Chen, S., Wang, H., & Hu, C. (2013). Circulating microRNA-92a and microRNA-21 as novel minimally invasive biomarkers for primary breast cancer. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-012-1315-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.